Ayoxxa Biosystems
 |
|
| Private | |
| Industry | Biotech |
| Founded | Singapore (2010), Germany (2012) |
| Founder | Andreas Schmidt, Dieter Trau |
| Headquarters | Cologne, Germany |
|
Key people
|
Rodney Turner (CEO), Dieter Trau (CSO), Markus Zumbansen (CTO), Andreas Richter (CFO) |
| Products | Development of a Protein chip platform based on the Bead-based Arrays, named LUNARIS (TM) multiplexing technology |
|
Production output
|
Biomarker Detection Kits |
| Services | Multiplexing and Readout Services, Assay Development Services |
| Owner | Andreas Schmidt, Dieter Trau, Wellington Partners, , High-Tech Gründerfonds, Rainer Christine, Gregor Siebenkotten, , b-to-v Partners, Creathor Venture, HR Ventures |
|
Number of employees
|
35 |
| Subsidiaries | Ayoxxa Living Health Technologies Pte. Ltd (Singapore) |
| Website | www |
Ayoxxa Biosystems (stylized in its logo as AYOXXA) is a biotechnology company founded in 2010 in Singapore, and headquartered in Germany.
The company is known for developing protein chip capable of detecting at once multiple biomarkers, biomarker signatures (including markers for cancer, allergies, age related macular degeneration AMD, or infectious diseases) from a small biological sample. The protein chip yields large amounts of data, being primarily aimed for use in biomedical research in academia, clinic and industry.
In 2006 the basic technology of the position-encoded bead-based Arrays multiplex protein chip began to be developed in the research labs of the Department of Bioengineering, at the National University of Singapore (NUS). The project was led by Dieter Trau, Assistant Professor at NUS' Department of Bioengineering and Department of Chemical and Biomolecular Engineering,
As a result, and with the continued support of NUS, the start-up Ayoxxa Living Health Technologies Pte. Ltd was founded in 2010. The rights to the intellectual property developed at NUS were exclusively licensed to Ayoxxa, for the company to further develop.
In 2012 the company expanded operations to Europe, establishing its headquarters in Cologne, Germany, as Ayoxxa Biosystems GmbH. The company now develops partnerships, services, commercialization and further research from its headquarters.
In December 2016, Ayoxxa Biosystems GmbH officially announced Mr. Rodney Turner as CEO and Dr. Markus Zumbansen as CTO. Dr. Andreas Schmidt stepped down from CEO position in October 2016 and remains associated with AYOXXA as Board Member.
Ayoxxa's protein chip or microarray technology enables the detection of large number of diseases through the protein analysis of a single droplet of blood or other bodily fluids. This technology contrasts with previously established methods which were restricted to a single point testing, requiring considerable amounts of biological sample, and limiting the amount of analytes tested from each sample.
...
Wikipedia